NOVACYT |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.819 EUR | +2.89% |
|
-1.33% | +14.87% |
| 19/04 | Novacyt: confident ahead of DHSC trial | CF |
| 19/04 | Novacyt expects court to dismiss application by UK DHSC | AN |
Novacyt develops, produces, and sells in vitro and molecular diagnostic products for the microbiology, haematology and serology markets. The activity is organized around two sectors:
- development of solutions and diagnostic services. The group is also developing a manufacturing activity for reagents and kits for bacterial and blood tests;
- manufacture and sale of molecular screening kits (Primerdesign): for laboratories.
Calendar
26/09/2024
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +14.87% | 61.68M | |
| -20.60% | 128M | |
| -7.82% | 67.46M | |
| +6.64% | 60.58M | |
| +0.60% | 51.45M |
- Stock Market
- Equities
- ALNOV Stock
- Funds and ETFs Novacyt
